Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), previews sessions to be presented at the ADA's 81st Scientific Sessions.
A lot of data at this year’s Scientific Sessions will reflect changes in pharmacological therapy in type 2 diabetes, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA). The virtual conference will take place June 25-29, 2021.
Transcript:
How is ADA’s collaboration with other disciplines bringing sodium glucose co-transporter 2 (SGLT-2s) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to more patients and earlier in their disease trajectory?
Really, one of the big changes in diabetes and pharmacological therapy of type 2 diabetes (T2D) has been the discovery of the cardiovascular benefits of SGLT-2 and GLP-1 receptor agonists. That is an evolving story. You'll see a lot of data at our Scientific Sessions that will be covering that. Part of this is really, how do we coordinate care more effectively? How do we ensure that the people that could benefit from these drugs, in fact do? Today, it's the minority of people that would be eligible, that are receiving these treatments. If you look at our standards of care, one of the big changes over the last year has been to elevate these treatments to consider use very early in the course of diabetes management for individuals that are at high risk for atherosclerotic cardiovascular disease or chronic kidney disease.
At this year’s Scientific Sessions, there are sessions that address the questions of genetic vs social influences in the development of diabetes, as well as the role of social stress on health. What have we learned in this area in recent years?
This broader area of social determinants of health have really taken on greater urgency. We've seen this play out in health disparities during the recent COVID-19 pandemic, and the disproportionate effect of the pandemic on people of color. You can see a lot of presentations focusing on this area. There was also a wonderful scientific review that was published by the American Diabetes Association that looks at this field in its entirety and identifies where the challenges are and some thoughts about what to do. I think you’ll see a number of presentations at the Scientific Sessions that will cover various aspects of health disparities. That dovetails with an effort by the American Diabetes Association around health equity. We have taken a strong stand on this area for all of the obvious reasons. In many ways, we feel that if we can address the inequities in health care for people with diabetes, it's going to be the same type of thing and same type of approaches beyond that. That includes anything from having access to healthy foods to having access to the technologies that can help people live healthier with their diabetes. On our website, at Health Equity Now, you can see a patient bill of rights that speaks to many of these issues of what we’re advocating for.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More